Meclofenamic Acid

Meclofenamic Acid

SCHEMBL106

Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ALOX5PTGS1PTGS2

The experimentally established mechanism targets of Meclofenamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 known ✓ P35354 7/20 1.00
PTGS1 known ✓ P23219 1/20 1.00
TTR P02766 2/20 1.00
MEN1 O00255 2/20 1.00
MAPK1 P28482 2/20 1.00
KMT2A Q03164 2/20 1.00
METTL3 Q86U44 2/20 1.00
AKR1B10 O60218 1/20 1.00
ABCB11 O95342 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
CHRM1 P11229 1/20 1.00
FABP2 P12104 1/20 1.00
RXRA P19793 1/20 1.00
TBXA2R P21731 1/20 1.00
NR4A1 P22736 1/20 1.00
PDE4A P27815 1/20 1.00
AKR1C3 P42330 1/20 1.00
NR4A2 P43354 1/20 1.00
AKR1C2 P52895 1/20 1.00
AKR1C1 Q04828 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Meclofenamic Acid SCHEMBL11543781 1.00 PTGS2 (1.00) PTGS2TTRMEN1MAPK1KMT2A
Meclofenamic Acid SCHEMBL29379636 1.00 PTGS2 (1.00) PTGS2TTRMEN1MAPK1KMT2A
Meclofenamic Acid SCHEMBL29373906 1.00 PTGS2 (1.00) PTGS2TTRMEN1MAPK1KMT2A
Meclofenamic Acid SCHEMBL17200177 0.99 PTGS2 (0.97) PTGS2TTRMEN1MAPK1KMT2A
Meclofenamic Acid SCHEMBL1320065 0.99 PTGS2 (0.97) PTGS2TTRMEN1MAPK1KMT2A
Meclofenamic Acid SCHEMBL8927120 0.99 PTGS2 (0.97) PTGS2TTRMEN1MAPK1KMT2A
Meclofenamic Acid SCHEMBL8193707 0.91 PTGS2 (0.83) PTGS2TTRMEN1MAPK1KMT2A
Meclofenamic Acid SCHEMBL18171844 0.91 PTGS2 (0.90) PTGS2TTRMEN1MAPK1KMT2A
Meclofenamic Acid SCHEMBL436190 0.91 PTGS2 (0.83) PTGS2TTRMEN1MAPK1KMT2A
SCHEMBL16689763 0.91 PTGS2 (0.83) PTGS2TTRMEN1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 48572 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747263-A1 LIPID NANOPARTICLES AND USES THEREOF University of Connecticut (US) 2026-05-27 EP claimed
WO-2026106917-A1 EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL BioPhysics Pharma, Inc. (US) 2026-05-21 WO claimed
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
WO-2026099781-A1 METHOD SANIA TX LTD (GB) 2026-05-15 WO claimed
WO-2026099804-A2 METHOD SANIA TX LTD (GB) 2026-05-15 WO claimed
US-20260130928-A1 COMBINATION OF AKR1C3 ACTIVATED ANTICANCER PRODRUG COMPOUND AND ANALGESIC DRUG FOR TREATING CANCER PATIENTS ACCOMPANIED BY PAIN ASCENTAWITS PHARMACEUTICALS LTD (CN) 2026-05-14 US claimed
EP-4741492-A2 NECROSIS INHIBITOR Linkgevity Limited (GB) 2026-05-13 EP claimed
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
US-20260115209-A1 COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER UNIV CALIFORNIA (US) 2026-04-30 US claimed
US-12605345-B2 Transdermal drug delivery system BioPhysics Pharma, Inc. (US) 2026-04-21 US claimed
EP-0180597-A1 COUGH/COLD MIXTURES COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS. SUNSHINE ABRAHAM (US) 1986-05-14 EP claimed
WO-1985004589-A1 COUGH/COLD MIXTURES COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS SUNSHINE ABRAHAM 1985-10-24 WO claimed
WO-1985003443-A1 ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING DIPHENHYDRAMINE AND METHODS OF USING SAME RICHARDSON-VICKS, INC. (US) 1985-08-15 WO claimed
EP-0039051-B1 MANNICH-BASE HYDROXAMIC ACID PRODRUGS FOR THE IMPROVED BIOAVAILABILITY OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS, A PROCESS FOR PREPARING AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM MERCK & CO. INC. (US) 1985-07-24 EP claimed
EP-0130524-A2 Depot antiphlogistics Troponwerke GmbH & Co. KG (DE) 1985-01-09 EP claimed
EP-0114886-A1 IMPROVED ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CAFFEINE. SUNSHINE ABRAHAM (US) 1984-08-08 EP claimed
WO-1984000490-A1 IMPROVED ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING CAFFEINE AND METHODS OF USING SAME SUNSHINE ABRAHAM 1984-02-16 WO claimed
EP-0051278-A1 Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same MERCK & CO. INC. (US) 1982-05-12 EP claimed
EP-0039051-A2 Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them MERCK & CO. INC. (US) 1981-11-04 EP claimed
US-4024279-A Treatment of dysmenorrhea and migraine symptoms YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) 1977-05-17 US claimed